

Manu Shankar-Hari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4951466/publications.pdf>

Version: 2024-02-01

177
papers

36,847
citations

30070

54
h-index

4228

174
g-index

210
all docs

210
docs citations

210
times ranked

42206
citing authors

#	ARTICLE	IF	CITATIONS
1	The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA - Journal of the American Medical Association, 2016, 315, 801.	7.4	16,554
2	Assessment of Clinical Criteria for Sepsis. JAMA - Journal of the American Medical Association, 2016, 315, 762.	7.4	2,727
3	Developing a New Definition and Assessing New Clinical Criteria for Septic Shock. JAMA - Journal of the American Medical Association, 2016, 315, 775.	7.4	1,622
4	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 384, 1491-1502.	27.0	1,419
5	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, 2020, 5, 1598-1607.	13.3	1,115
6	Genetic mechanisms of critical illness in COVID-19. Nature, 2021, 591, 92-98.	27.8	1,014
7	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New England Journal of Medicine, 2021, 385, 790-802.	27.0	778
8	A dynamic COVID-19 immune signature includes associations with poor prognosis. Nature Medicine, 2020, 26, 1623-1635.	30.7	765
9	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1317.	7.4	671
10	A living WHO guideline on drugs for covid-19. BMJ, The, 2020, 370, m3379.	6.0	664
11	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	7.4	498
12	Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock. JAMA - Journal of the American Medical Association, 2016, 316, 509.	7.4	456
13	Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 691-698.	10.7	455
14	Determinant-Based Classification of Acute Pancreatitis Severity. Annals of Surgery, 2012, 256, 875-880.	4.2	425
15	Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nature Medicine, 2022, 28, 410-422.	30.7	392
16	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respiratory Medicine,the, 2021, 9, 622-642.	10.7	371
17	Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. Nature Medicine, 2020, 26, 1701-1707.	30.7	315
18	The immunology of sepsis. Immunity, 2021, 54, 2450-2464.	14.3	263

#	ARTICLE	IF	CITATIONS
19	Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study. <i>BMJ</i> , The, 2021, 374, n1931.	6.0	217
20	A guide to immunotherapy for COVID-19. <i>Nature Medicine</i> , 2022, 28, 39-50.	30.7	206
21	Current gaps in sepsis immunology: new opportunities for translational research. <i>Lancet Infectious Diseases</i> , The, 2019, 19, e422-e436.	9.1	205
22	Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database. <i>British Journal of Anaesthesia</i> , 2017, 119, 626-636.	3.4	177
23	Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 1209-1218.	10.7	174
24	Whole-genome sequencing reveals host factors underlying critical COVID-19. <i>Nature</i> , 2022, 607, 97-103.	27.8	174
25	Effect of Convalescent Plasma on Organ Supportâ€Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	7.4	169
26	Rapid Diagnosis of Infection in the Critically Ill, a Multicenter Study of Molecular Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections*. <i>Critical Care Medicine</i> , 2015, 43, 2283-2291.	0.9	159
27	Redefining critical illness. <i>Nature Medicine</i> , 2022, 28, 1141-1148.	30.7	136
28	Understanding Long-Term Outcomes Following Sepsis: Implications and Challenges. <i>Current Infectious Disease Reports</i> , 2016, 18, 37.	3.0	124
29	SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. <i>Nature Communications</i> , 2021, 12, 3406.	12.8	122
30	Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. <i>Critical Care</i> , 2021, 25, 106.	5.8	121
31	COVID-19 in critical care: epidemiology of the first epidemic wave across England, Wales and Northern Ireland. <i>Intensive Care Medicine</i> , 2020, 46, 2035-2047.	8.2	117
32	Trends in Intensive Care for Patients with COVID-19 in England, Wales, and Northern Ireland. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 565-574.	5.6	117
33	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	14.3	112
34	Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. <i>Intensive Care Medicine</i> , 2018, 44, 627-635.	8.2	97
35	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). <i>Intensive Care Medicine</i> , 2018, 44, 438-448.	8.2	96
36	Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. <i>Critical Care</i> , 2011, 16, 206.	5.8	95

#	ARTICLE	IF	CITATIONS
37	The diagnostic and prognostic significance of monitoring blood levels of immature neutrophils in patients with systemic inflammation. <i>Critical Care</i> , 2015, 19, 57.	5.8	94
38	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	13.3	94
39	Evidence for a causal link between sepsis and long-term mortality: a systematic review of epidemiologic studies. <i>Critical Care</i> , 2016, 20, 101.	5.8	87
40	Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19. <i>Acta Neuropathologica</i> , 2020, 140, 397-400.	7.7	85
41	Activation-Associated Accelerated Apoptosis of Memory B Cells in Critically Ill Patients With Sepsis. <i>Critical Care Medicine</i> , 2017, 45, 875-882.	0.9	83
42	Effect of Antiplatelet Therapy on Survival and Organ Support—Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247.	7.4	83
43	Sepsis Subclasses: A Framework for Development and Interpretation*. <i>Critical Care Medicine</i> , 2021, 49, 748-759.	0.9	81
44	Corticosteroid therapy for sepsis: a clinical practice guideline. <i>BMJ: British Medical Journal</i> , 2018, 362, k3284.	2.3	76
45	Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 543-552.	5.6	74
46	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. <i>Intensive Care Medicine</i> , 2021, 47, 867-886.	8.2	65
47	An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.. <i>Health Technology Assessment</i> , 2012, 16, 1-186.	2.8	65
48	Differences in Impact of Definitional Elements on Mortality Precludes International Comparisons of Sepsis Epidemiology—A Cohort Study Illustrating the Need for Standardized Reporting*. <i>Critical Care Medicine</i> , 2016, 44, 2223-2230.	0.9	63
49	Risk Factors at Index Hospitalization Associated With Longer-term Mortality in Adult Sepsis Survivors. <i>JAMA Network Open</i> , 2019, 2, e194900.	5.9	63
50	ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 691.	1.6	62
51	The intensive care medicine research agenda on septic shock. <i>Intensive Care Medicine</i> , 2017, 43, 1294-1305.	8.2	61
52	Prognostic Factors for 30-Day Mortality in Critically Ill Patients With Coronavirus Disease 2019: An Observational Cohort Study. <i>Critical Care Medicine</i> , 2021, 49, 102-111.	0.9	61
53	Continuous renal replacement therapy (CRRT) in patients with liver disease: Is circuit life different?. <i>Journal of Hepatology</i> , 2009, 51, 504-509.	3.7	60
54	Sepsis hysteria: excess hype and unrealistic expectations. <i>Lancet, The</i> , 2019, 394, 1513-1514.	13.7	60

#	ARTICLE	IF	CITATIONS
55	The educational environment for training in intensive care medicine: structures, processes, outcomes and challenges in the European region. <i>Intensive Care Medicine</i> , 2009, 35, 1575-1583.	8.2	59
56	Immune Activation in Sepsis. <i>Critical Care Clinics</i> , 2018, 34, 29-42.	2.6	59
57	Early PREdiction of sepsis using leukocyte surface biomarkers: the ExPRES-sepsis cohort study. <i>Intensive Care Medicine</i> , 2018, 44, 1836-1848.	8.2	59
58	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e498-e506.	3.9	58
59	Endogenous IgG hypogammaglobulinaemia in critically ill adults with sepsis: systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2015, 41, 1393-1401.	8.2	57
60	Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study. <i>Critical Care</i> , 2018, 22, 95.	5.8	56
61	International variation in the management of severe COVID-19 patients. <i>Critical Care</i> , 2020, 24, 486.	5.8	55
62	Rate and risk factors for rehospitalisation in sepsis survivors: systematic review and meta-analysis. <i>Intensive Care Medicine</i> , 2020, 46, 619-636.	8.2	53
63	Association of cardiometabolic microRNAs with COVID-19 severity and mortality. <i>Cardiovascular Research</i> , 2022, 118, 461-474.	3.8	51
64	Do we need a new definition of sepsis?. <i>Intensive Care Medicine</i> , 2015, 41, 909-911.	8.2	47
65	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , 2021, 21, 1170.	2.9	46
66	International standards for programmes of training in intensive care medicine in Europe. <i>Intensive Care Medicine</i> , 2011, 37, 385-393.	8.2	44
67	Population enrichment for critical care trials: phenotypes and differential outcomes. <i>Current Opinion in Critical Care</i> , 2019, 25, 489-497.	3.2	40
68	Paediatric Inflammatory Multisystem Syndrome Temporally-Associated with SARS-CoV-2 Infection: An Overview. <i>Intensive Care Medicine</i> , 2021, 47, 90-93.	8.2	40
69	Acute respiratory distress syndrome (ARDS) phenotyping. <i>Intensive Care Medicine</i> , 2019, 45, 516-519.	8.2	38
70	Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. <i>EBioMedicine</i> , 2022, 76, 103856.	6.1	38
71	Redox State of Pentraxin 3 as a Novel Biomarker for Resolution of Inflammation and Survival in Sepsis. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 2545-2557.	3.8	37
72	Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine (StEP) initiative: infection and sepsis. <i>British Journal of Anaesthesia</i> , 2019, 122, 500-508.	3.4	34

#	ARTICLE	IF	CITATIONS
73	Precision medicine in acute respiratory distress syndrome: workshop report and recommendations for future research. <i>European Respiratory Review</i> , 2021, 30, 200317.	7.1	34
74	Changes in temperature management and outcome after out-of-hospital cardiac arrest in United Kingdom intensive care units following publication of the targeted temperature management trial. <i>Resuscitation</i> , 2021, 162, 304-311.	3.0	32
75	Towards a biological definition of ARDS: are treatable traits the solution?. <i>Intensive Care Medicine Experimental</i> , 2022, 10, 8.	1.9	32
76	The use of enrichment to reduce statistically indeterminate or negative trials in critical care. <i>Anaesthesia</i> , 2017, 72, 560-565.	3.8	30
77	Relationship between norepinephrine dose, tachycardia and outcome in septic shock: A multicentre evaluation. <i>Journal of Critical Care</i> , 2020, 57, 185-190.	2.2	30
78	Estimating attributable fraction of mortality from sepsis to inform clinical trials. <i>Journal of Critical Care</i> , 2018, 45, 33-39.	2.2	29
79	Lung Recruitability in Severe Acute Respiratory Distress Syndrome Requiring Extracorporeal Membrane Oxygenation. <i>Critical Care Medicine</i> , 2019, 47, 1177-1183.	0.9	29
80	International survey on the management of mechanical ventilation during ECMO in adults with severe respiratory failure. <i>Minerva Anestesiologica</i> , 2015, 81, 1170-83, 77 p following 1183.	1.0	29
81	Heterogeneity of treatment effect by baseline risk of mortality in critically ill patients: re-analysis of three recent sepsis and ARDS randomised controlled trials. <i>Critical Care</i> , 2019, 23, 156.	5.8	27
82	Relationship between Anaemia, Haemolysis, Inflammation and Haem Oxygenase-1 at Admission with Sepsis: a pilot study. <i>Scientific Reports</i> , 2018, 8, 11198.	3.3	26
83	Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1345-1347.	9.1	26
84	Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial. <i>Critical Care</i> , 2014, 18, 649.	5.8	24
85	Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial. <i>Trials</i> , 2020, 21, 462.	1.6	24
86	Readmission Diagnoses After Pediatric Severe Sepsis Hospitalization*. <i>Critical Care Medicine</i> , 2019, 47, 583-590.	0.9	23
87	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation. <i>PLoS ONE</i> , 2021, 16, e0256813.	2.5	23
88	Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) trial: A phase 1 trial. <i>EClinicalMedicine</i> , 2021, 41, 101167.	7.1	22
89	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , 2022, 141, 147-173.	3.8	22
90	Judging quality of current septic shock definitions and criteria. <i>Critical Care</i> , 2015, 19, 445.	5.8	20

#	ARTICLE	IF	CITATIONS
91	qSOFA, Cue Confusion. <i>Annals of Internal Medicine</i> , 2018, 168, 293.	3.9	20
92	Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 595-605.	4.0	20
93	Acute Respiratory Distress Syndrome Phenotypes and Identifying Treatable Traits. The Dawn of Personalized Medicine for ARDS. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 280-281.	5.6	20
94	Can Concurrent Abnormalities in Free Light Chains and Immunoglobulin Concentrations Identify a Target Population for Immunoglobulin Trials in Sepsis?*. <i>Critical Care Medicine</i> , 2017, 45, 1829-1836.	0.9	19
95	Acceptance and transfer to a regional severe respiratory failure and veno-venous extracorporeal membrane oxygenation (ECMO) service: predictors and outcomes. <i>Anaesthesia</i> , 2018, 73, 177-186.	3.8	19
96	Major surgery and the immune system: from pathophysiology to treatment. <i>Current Opinion in Critical Care</i> , 2018, 24, 588-593.	3.2	19
97	Physiological dead space ventilation, disease severity and outcome in ventilated patients with hypoxaemic respiratory failure due to coronavirus disease 2019. <i>Intensive Care Medicine</i> , 2020, 46, 2092-2093.	8.2	19
98	The interaction between arterial oxygenation and carbon dioxide and hospital mortality following out of hospital cardiac arrest: a cohort study. <i>Critical Care</i> , 2020, 24, 336.	5.8	18
99	Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2897.	4.1	17
100	Accounting for Heterogeneity in Relative Treatment Effects for Use in Cost-Effectiveness Models and Value-of-Information Analyses. <i>Medical Decision Making</i> , 2015, 35, 608-621.	2.4	16
101	Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials. <i>Critical Care</i> , 2020, 24, 449.	5.8	16
102	Demographic Shifts, Case Mix, Activity, and Outcome for Elderly Patients Admitted to Adult General ICUs in England, Wales, and Northern Ireland. <i>Critical Care Medicine</i> , 2020, 48, 466-474.	0.9	16
103	Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis. <i>PLoS ONE</i> , 2022, 17, e0270668.	2.5	16
104	Immunoglobulins and sepsis. <i>Intensive Care Medicine</i> , 2018, 44, 1923-1925.	8.2	15
105	A Comparison of Mortality From Sepsis in Brazil and England. <i>Critical Care Medicine</i> , 2019, 47, 76-84.	0.9	15
106	Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial. <i>Critical Care</i> , 2022, 26, .	5.8	15
107	Activated protein C in severe acute pancreatitis without sepsis? Not just yet <i>Critical Care</i> , 2010, 14, 188.	5.8	14
108	Healthcare-associated bloodstream infections in critically ill patients: descriptive cross-sectional database study evaluating concordance with clinical site isolates. <i>Annals of Intensive Care</i> , 2014, 4, 34.	4.6	14

#	ARTICLE	IF	CITATIONS
109	Septic shock resuscitation in the first hour. <i>Current Opinion in Critical Care</i> , 2017, 23, 561-566.	3.2	14
110	Goodbye SIRS? Innate, trained and adaptive immunity and pathogenesis of organ dysfunction. <i>Medizinische Klinik - Intensivmedizin Und Notfallmedizin</i> , 2020, 115, 10-14.	1.1	14
111	Current Understanding of Leukocyte Phenotypic and Functional Modulation During Extracorporeal Membrane Oxygenation: A Narrative Review. <i>Frontiers in Immunology</i> , 2020, 11, 600684.	4.8	14
112	An international survey of nutrition practices in adult patients receiving veno-venous ECMO. <i>Intensive Care Medicine Experimental</i> , 2015, 3, .	1.9	13
113	Outcomes in mechanically ventilated patients with hypoxaemic respiratory failure caused by COVID-19. <i>British Journal of Anaesthesia</i> , 2020, 125, e480-e483.	3.4	13
114	Impact of differences in acute respiratory distress syndrome randomised controlled trial inclusion and exclusion criteria: systematic review and meta-analysis. <i>British Journal of Anaesthesia</i> , 2021, 127, 85-101.	3.4	13
115	Reflections on Critical Care's Past, Present, and Future. <i>Critical Care Medicine</i> , 2021, 49, 1855-1865.	0.9	13
116	Do Sepsis-3 Criteria Facilitate Earlier Recognition of Sepsis and Septic Shock? A Retrospective Cohort Study. <i>Shock</i> , 2019, 51, 306-311.	2.1	12
117	Development, Validation, and Clinical Utility Assessment of a Prognostic Score for 1-Year Unplanned Rehospitalization or Death of Adult Sepsis Survivors. <i>JAMA Network Open</i> , 2020, 3, e2013580.	5.9	12
118	Rethinking animal models of sepsis – working towards improved clinical translation whilst integrating the 3Rs. <i>Clinical Science</i> , 2020, 134, 1715-1734.	4.3	12
119	Divide and conquer: identifying acute respiratory distress syndrome subphenotypes. <i>Thorax</i> , 2017, 72, 867-869.	5.6	11
120	Defining phenotypes and treatment effect heterogeneity to inform acute respiratory distress syndrome and sepsis trials: secondary analyses of three RCTs. <i>Efficacy and Mechanism Evaluation</i> , 2021, 8, 1-104.	0.7	11
121	Lessons From ARDS for Non-ARDS Research. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1863.	7.4	10
122	Focus on sepsis. <i>Intensive Care Medicine</i> , 2019, 45, 1459-1461.	8.2	10
123	Should we consider blocking the inhibitory immune checkpoint molecules for treating T cell exhaustion in sepsis?. <i>Intensive Care Medicine</i> , 2020, 46, 119-121.	8.2	10
124	Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study. <i>BMJ Open</i> , 2021, 11, e055435.	1.9	10
125	Retropharyngeal abscess presenting with upper airway obstruction. <i>Anaesthesia</i> , 2003, 58, 714-715.	3.8	9
126	Disrupted Peyer's Patch Microanatomy in COVID-19 Including Germinal Centre Atrophy Independent of Local Virus. <i>Frontiers in Immunology</i> , 2022, 13, 838328.	4.8	9

#	ARTICLE	IF	CITATIONS
127	Quantitative Assessment of the Effects of Therapeutic Hypothermia on Early Repolarization in Idiopathic Ventricular Fibrillation Survivors. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2014, 7, 120-126.	4.8	8
128	Predictive value of cell-surface markers in infections in critically ill patients: protocol for an observational study (ImmuNe FailurE in Critical Therapy (INFECT) Study). <i>BMJ Open</i> , 2016, 6, e011326.	1.9	8
129	How could we enhance translation of sepsis immunology to inform immunomodulation trials in sepsis?. <i>Critical Care</i> , 2017, 21, 125.	5.8	8
130	Long-term adherence to a 5 day antibiotic course guideline for treatment of intensive care unit (ICU)-associated Gram-negative infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1688-1694.	3.0	7
131	How might a diagnostic microRNA signature be used to speed up the diagnosis of sepsis?. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 249-251.	3.1	7
132	37th International Symposium on Intensive Care and Emergency Medicine (part 3 of 3). <i>Critical Care</i> , 2017, 21, .	5.8	7
133	Translational Research in the Time of COVID-19â€”Dissolving Boundaries. <i>PLoS Pathogens</i> , 2020, 16, e1008898.	4.7	7
134	Critical care outcomes, for the first 200 patients with confirmed COVID-19, in England, Wales and Northern Ireland: A report from the ICNARC Case Mix Programme. <i>Journal of the Intensive Care Society</i> , 2021, 22, 270-279.	2.2	7
135	Could stress ulcer prophylaxis increase mortality in high-acuity patients?. <i>Intensive Care Medicine</i> , 2020, 46, 793-795.	8.2	7
136	Maternal Risk Modeling in Critical Careâ€”Development of a Multivariable Risk Prediction Model for Death and Prolonged Intensive Care*. <i>Critical Care Medicine</i> , 2020, 48, 663-672.	0.9	7
137	Degradation of the Endothelial Glycocalyx Contributes to Metabolic Acidosis in Children Following Cardiopulmonary Bypass Surgery. <i>Pediatric Critical Care Medicine</i> , 2021, 22, e571-e581.	0.5	7
138	Delirium in COVID-19: can we make the unknowns knowns?. <i>Intensive Care Medicine</i> , 2021, 47, 1144-1147.	8.2	6
139	The REMDACTA trial: do interleukin receptor antagonists provide additional benefit in COVID-19?. <i>Intensive Care Medicine</i> , 2021, 47, 1315-1318.	8.2	6
140	The influence of statin exposure on inflammatory markers in patients with early bacterial infection: pilot prospective cohort study. <i>BMC Anesthesiology</i> , 2014, 14, 106.	1.8	5
141	Early PREdiction of Severe Sepsis (ExPRES-Sepsis) study: protocol for an observational derivation study to discover potential leucocyte cell surface biomarkers. <i>BMJ Open</i> , 2016, 6, e011335.	1.9	5
142	In Pursuit of Precision Medicine in the Critically Ill. Annual Update in Intensive Care and Emergency Medicine, 2018, , 649-658.	0.2	5
143	Race, Ethnicity, and Sepsis: Beyond Adjusted Odds Ratios*. <i>Critical Care Medicine</i> , 2018, 46, 1009-1010.	0.9	5
144	Trials on oxygen supplementation in sepsis: better late than never. <i>Intensive Care Medicine</i> , 2020, 46, 116-118.	8.2	5

#	ARTICLE	IF	CITATIONS
145	Cellular and molecular mechanisms of IMMunE dysfunction and Recovery from SEpsis-related critical illness in adults: An observational cohort study (IMMERSE) protocol paper. Journal of the Intensive Care Society, 2022, 23, 318-324.	2.2	5
146	Lack of Clinical Benefit of Interferon Î²-1a Among Patients With Severe Acute Respiratory Distress Syndrome. JAMA - Journal of the American Medical Association, 2020, 323, 713.	7.4	5
147	A Proteomics-Based Assessment of Inflammation Signatures in Endotoxemia. Molecular and Cellular Proteomics, 2021, 20, 100021.	3.8	5
148	Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR. Journal of Clinical Microbiology, 2022, 60, e0228321.	3.9	5
149	Defining Septic Shockâ€”Reply. JAMA - Journal of the American Medical Association, 2016, 316, 456.	7.4	4
150	Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial. BMJ Open, 2020, 10, e038847.	1.9	4
151	Utilising mass cytometry with CD45 barcoding and standardised leucocyte phenotyping for immune trajectory assessment in critically ill patients. British Journal of Anaesthesia, 2021, 126, e149-e152.	3.4	4
152	Initial setting of high-flow nasal oxygen post extubation based on mean inspiratory flow during a spontaneous breathing trial. Journal of Critical Care, 2021, 63, 40-44.	2.2	4
153	A life-threatening sore throat masquerading as swine flu. Lancet, The, 2010, 375, 524.	13.7	3
154	Statin therapy in critical illness: an international survey of intensive care physiciansâ€™ opinions, attitudes and practice. BMC Clinical Pharmacology, 2012, 12, 13.	2.5	3
155	Outcomes of critically ill COVID-19 patients managed in a high-volume severe respiratory failure and ECMO centre in the United Kingdom. Journal of the Intensive Care Society, 2022, 23, 233-236.	2.2	3
156	Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial. Trials, 2022, 23, 401.	1.6	3
157	Albumin versus balanced crystalloid for resuscitation in the treatment of sepsis: A protocol for a randomised controlled feasibility study, â€œABC-Sepsisâ€ Journal of the Intensive Care Society, 0, , 175114372211036.	2.2	3
158	Fatal cardiovascular instability secondary to hypercalcaemia and intracellular calcium deposition complicating T-cell leukaemia-lymphoma. JRSO Open, 2016, 7, 205427041560811.	0.5	2
159	ARDS subphenotypes: searching for Rorschach among the roentgenograms?. Thorax, 2022, 77, 2-4.	5.6	2
160	Towards an ecological definition of sepsis: a viewpoint. Intensive Care Medicine Experimental, 2021, 9, 63.	1.9	2
161	The Impact of Sample Size Misestimations on the Interpretation of ARDS Trials. Chest, 2022, 162, 1048-1062.	0.8	2
162	Protocol for a scoping review of sepsis epidemiology. Systematic Reviews, 2022, 11, .	5.3	2

#	ARTICLE	IF	CITATIONS
163	Neurogenic diabetes insipidus presenting in a patient with subacute liver failure: a case report. Journal of Medical Case Reports, 2010, 4, 232.	0.8	1
164	The critically ill patient: making the referral to intensive care. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, M154-M156.	0.5	1
165	The critically ill patient: identification and initial stabilization. British Journal of Hospital Medicine (London, England: 2005), 2011, 72, M138-M140.	0.5	1
166	Just Because Things Are Not Different, Does Not Mean They Are the Same. Critical Care Medicine, 2017, 45, 1955-1957.	0.9	1
167	Use of Hydrocortisone Based on Plasma Biomarkers in Patients with Septic Shock: Another One Bites the Dust?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 644-646.	5.6	1
168	Immunological Subpopulations Within Critically Ill COVID-19 Patients. Chest, 2021, 159, 1706-1708.	0.8	1
169	Is T Cell Exhaustion a Treatable Trait in Sepsis?. Annual Update in Intensive Care and Emergency Medicine, 2020, , 271-279.	0.2	1
170	Utility of an antibiotic guideline in hospital-associated infections. Critical Care, 2010, 14, P51.	5.8	0
171	Prevalence of Gram-negative bacilli resistance in adult critically ill patients at admission screening. Critical Care, 2011, 15, .	5.8	0
172	P258Redox-state of pentraxin 3 as a novel biomarker for resolution of inflammation and survival in sepsis. Cardiovascular Research, 2014, 103, S46.3-S46.	3.8	0
173	IMPACT OF TRIALS ON CLINICAL PRACTICE: INTERVENTIONS IN SEPTIC SHOCK PATIENTS BETWEEN 2005 AND 2013. Intensive Care Medicine Experimental, 2015, 3, .	1.9	0
174	Activation-associated death of memory b cells in peripheral circulation in adults with sepsis. Intensive Care Medicine Experimental, 2015, 3, .	1.9	0
175	Does sepsis cause increased long-term mortality? a systematic review. Intensive Care Medicine Experimental, 2015, 3, .	1.9	0
176	Protocolised early goal-directed therapy in patients with sepsis/septic shock does not result in improved survival compared with usual care with less invasive resuscitation strategies. Evidence-Based Medicine, 2017, 22, 223-223.	0.6	0
177	Caring for Sepsis Patients: An Update. Critical Care Clinics, 2018, 34, xlii-xv.	2.6	0